Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | ADCLEC.SYN1: combinatorial CAR shows preclinical potential for R/R AML

Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the rationale for a chimeric antigen receptor (CAR) designed to target both ADGRE2 and CLEC12A in order to enhance anti-leukemic efficacy without increasing toxicity in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). ADGRE2 and CLEC12A are both highly co-expressed in AML, but with low levels of overlapping expression in normal cells. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.


Sascha Haubner, MD, has received research support from Takeda Pharmaceutical Company Ltd.